

Department of Psychiatry and Neurosciences

USF Health · College of Medicine

Office of the Chair - Week of October 10 - 14, 2011

Website: <http://www.hsc.usf.edu/PSYCH/>

Newsletter

Meetings

Tuesday 10/11/11 12:00 noon No Grand Rounds due to PRITE. Good luck to our Residents!

Thursday 10/13/11 8:00 a.m. Call Center Meeting

Resident Lectures:

8:00 a.m. PGY-1, PGY-2, PGY-3, PGY-4, CHILD – PRITE
 9:00 a.m. PGY-1, PGY-2, PGY-3, PGY-4, CHILD – PRITE
 10:00 a.m. PGY-1, PGY-2, PGY-3, PGY-4, CHILD – PRITE
 11:00 a.m. Residents' Meeting

Friday 10/14/11

Third Year Medical Student Lectures:

8:00 a.m. "Psychiatric Emergencies" Dr. Sandra Stock
 9:00 a.m. "Delirium" Dr. Barbara Lubrano
 10:00 a.m. "Capacity for Decision Making" Dr. Barbara Lubrano
 11:00 a.m. "Eating Disorders" Dr. Pauline Powers
 1:00 p.m. "Alcohol Dependence and Substance Abuse"
 Dr. Gabriel de Erausquin
 2:00 p.m. "Coma and Brain Death" Dr. Heber Varela
 3:00 p.m. "Cognitive Behavioral Neurology" Dr. Michael Hoffman
 4:00 p.m. "Movement Disorders" Dr. Robert Hauser

In The Know!

Happy Birthday wishes to Dr. Jamie Fernandez/October 14th, Elizabeth Marsh/October 15th and Ofelia Granadillo/October 16th.

The Annual Meeting of the membership of the USF Physicians Group will be held on Monday, October 31, 2011, at 5:30 p.m. at the Morsani Center for Advanced Healthcare, Conference Rooms 1013A and B. All USFPG Physician Members are invited to attend. A cocktail reception will be held from 5:00 – 5:30 p.m. followed by the business meeting from 5:30 – 6:30 p.m. Parking is available in the Laurel Parking Garage.

On October 14, 2011 from 7:00 – 10:00 p.m. Reel to Real will present “Lemon Tree (2008)” at The Carter-Jenkins Center. This session will be directed by Frances Marton, MSW, Associate Director, The Carter-Jenkins Center.

For information regarding the USF Memory Disorders Clinic, please click on the following link: http://health.usf.edu/medicine/psychiatry/p_memory_disorders_clinic.htm

Research Happenings!

Current Open Studies – Call [813-974-2832](tel:813-974-2832) or [813-974-1404](tel:813-974-1404) for more information on any study or to refer a patient.

Bipolar I Disorder with Depressive Symptoms

The Department is participating in a nationwide clinical research study evaluating the efficacy and safety of an investigational medication used as adjunctive therapy in patients with major depression associated with Bipolar I Disorder. This is a 15-week outpatient study. Patients must be 18-65 years of age and currently experiencing depressive symptoms. Patients must be on Lithium, Depakote, Lamictal, Abilify, Zyprexa, Risperdal, CONSTA, or Geodon. Assistance in obtaining Lithium and Depakote is available during the course of the study. Principal Investigator – Carlos Santana, M.D.

Schizophrenia PRIDE Study – Jail Recidivism

A 15- month open label study comparing oral antipsychotic treatment to paliperidone palmitate injections in delaying arrest recidivism in adults with Schizophrenia. Subjects must have been incarcerated at least twice in the last 24 months with the last release from jail occurring within 90 days prior to screening. Subjects receive antipsychotic medications at no charge. Principal Investigator – Jean Fils, M.D.

NEW AUTISM STUDY

We are happy to announce USF Psychiatry’s participation in a Phase 4, Safety and Efficacy study of Aripiprazole in the long-term maintenance treatment of children and adolescents 6-17 years of age with irritability associated with Autistic Disorder. The study is divided into three phases – a 7-42 day screening period, a 13-26 week single-blind phase, and a 16-week double-blind, placebo-controlled phase. Kids ages 6-17 with autism are eligible to screen for this study. Call 813-974-2832 for more information. Principal Investigator – Mike Bengtson, MD.

Now Open and Enrolling – ADHD Aggression Study

Kids between the ages of 6-12 years old and in generally good health with a diagnosis of ADHD are eligible to participate in a 10-week investigational medication trial . Children must be receiving stimulant medication treatment for ADHD symptoms for 1 month prior to study enrollment and be experiencing aggressive behaviors. This study is a 10 week investigational medication trial that will test the effectiveness and safety of molindone hydrochloride extended release as an add-on treatment for aggressive behaviors in children with ADHD. Principal Investigator – Mike Bengtson, MD.

Coming Soon – Bipolar I in Teens

This study is a 3- week investigational medication trial that will test the effectiveness and safety of asenapine compared to placebo in teens ages 12-17 with Bipolar I disorder who are currently experiencing a manic or mixed episode. A 26-week extension study is available. Study medication, study visits, and required laboratory work provided at no cost. Volunteers must be between the ages of 12-17 years old and in generally good health with a diagnosis of Bipolar I disorder and currently experiencing manic or mixed symptoms. Principal Investigator – Mike Bengtson, MD.

Study-related care will include a comprehensive diagnostic exam, physical exam, laboratory testing, ECG and frequent doctor visits, as well as investigational medication, all at no charge. This is a placebo controlled trial and all participants who complete the study will have the option to enroll in an open label 6 month extension study. Enrolled patients will be compensated for time and travel.

<http://health.usf.edu/medicine/psychiatry/research/index.htm>

Quality of Life in Youth with Tic Disorders

A one-time study visit evaluating the quality of life in youth with tic disorders, specifically on various aspects of family functioning and the daily challenges faced by children and their families. Children ages 6-17 years old with a diagnosis of a tic disorder (i.e. Chronic tic disorder or Tourette Syndrome) and are experiencing current tics are eligible to participate. This study is a one-time visit that will include questionnaires and assessments. Participants will also have the opportunity to attend a focus group with youth of similar age assessing kinds of help they received and accessibility of services and the difficulties faced by having tics.

Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Child and Adolescent Tourette's Disorder Guanfacine Clinical Trial

The purpose of this research study is to learn more about the new extended release formula of the drug, guanfacine. This new formula is called *Intuniv*. This study will help us understand how safe and how well this new extended release formula of guanfacine works for children with chronic tics. Your child is being asked to take part in this research study because he/she has been diagnosed with Chronic Motor or Vocal Tic Disorder or Tourette's Disorder. Main symptoms are motor tics such as uncontrolled movements and/or vocal tics such as repeated noises. These tics occur many times a day, nearly every day lasting for at least one year. Children ages 6-17 years old are eligible to participate.

Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Living with Tics

The Living with Tics research study hopes to show how well a type of psychotherapy helps children better cope with tics and become more resilient. Children who are interested to participate must attend an initial assessment to determine eligibility. Eligible participants must be between 8 and 18 years of age, have a diagnosis of Tourette Syndrome or Chronic Tic Disorder, experience tic-related impairment, and either be medication-free or on stable medication. If eligible, interested participants will be randomly assigned to receive immediate psychotherapy or a 10 week waitlist control condition followed by subsequent psychotherapy. As part of the study, there is no charge for the psychotherapy treatment. The immediate psychotherapy condition consists of weekly therapy sessions over a 10 week period. This multi-component treatment approach includes habit reversal training, anger management, problem solving skills and other related therapeutic components to help improve the quality of life for children with chronic tic disorders.

Please call (727) 767-8230 for more information.

Principal Investigator: Eric Storch PhD

Adult OCD Ondansetron Clinical Trial

The purpose of this research study is to investigate the effectiveness, safety, and tolerability of 2 dosages Ondansetron as compared to placebo (a substance which looks like an active drug but has no active ingredient) in adult who have OCD and who are currently taking a selective serotonin reuptake inhibitor (SRI) such as Anafranil® (clomipramine) Paxil® (paroxetine), Prozac® (fluoxetine), Luvox® (fluvoxamine, or Zoloft® (sertraline). Another purpose of this study is to find out how the study drug works in the body when taken along with an SSRI.

Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Pediatric OCD D-Cycloserine and Cognitive Behavioral Therapy (CBT) Research Study

The purpose of this research study is to examine if d-cycloserine enhances cognitive behavioral therapy for pediatric OCD. Participants will be involved in fifteen clinical visits spanning a nine-month period. Each participant will receive ten sessions of cognitive behavioral therapy and seven doses of the study medication or placebo one hour prior to session. Children ages 7-17 years old are eligible to participate.

Please call (727) 767-8230 for more information.

Principal Investigator: Eric Storch PhD

Cognitive-Behavioral Therapy (CBT) for Anxiety Disorders in Children with Autism Spectrum Disorder Research Study

The purpose of this research study is to examine the efficacy of a manualized cognitive-behavioral therapy to treat anxiety disorders in children with autism spectrum disorders. Therapy sessions last approximately one hour a week for sixteen weeks. In addition, participants will be involved in a number of anxiety and developmental assessments free of charge. Children ages 7-16 years old are eligible to participate.

Please call (727) 767-8230 for more information.

Principal Investigator: Eric Storch PhD